BiotechTube
Xynomic Pharmaceuticals

Xynomic Pharmaceuticals

Hangzhou, China· Est.

A clinical-stage oncology biotech in-licensing and developing novel small molecule therapies for global markets, with a lead asset in pivotal trials.

xynomicpharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

AI Company Overview

A clinical-stage oncology biotech in-licensing and developing novel small molecule therapies for global markets, with a lead asset in pivotal trials.

Oncology

Technology Platform

The company's core activity is the clinical development of in-licensed small molecule oncology drug candidates, with a focus on HDAC inhibitors like abexinostat.

Opportunities

Major opportunity lies in the potential approval and commercialization of abexinostat for renal cell carcinoma in China, a large market with high unmet need.
The Fast-Track designation in follicular lymphoma provides a pathway for accelerated US development.

Risk Factors

Key risks include clinical trial failure of the lead asset in Phase 3, competition from other HDAC inhibitors and novel RCC therapies, and challenges in building commercial capabilities as a pre-revenue company.

Competitive Landscape

Competes in the HDAC inhibitor space with drugs like vorinostat and belinostat, and in RCC with tyrosine kinase inhibitors and immunotherapies. Differentiation is sought through abexinostat's specific pharmacokinetic profile and combination strategy with checkpoint inhibitors.

More companies in China →